Skip to main content
OpenTrials
Not yet recruiting

NCT Number: NCT07774455

Pacritinib Effectiveness in Real-world Settings

This study aims to evaluate real-world treatment patterns and effectiveness of pacritinib, including hematologic and clinical outcomes, and survival through a site-based retrospective chart review of medical records of patients with MF.

Not yet recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Myelofibrosis (MF) Bone Marrow Diseases Hematologic Diseases Hemic and Lymphatic Diseases Myeloproliferative Disorders Primary Myelofibrosis

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

About this study

This is a multicenter, observational, retrospective chart review study of patients with Myelofibrosis (MF) who received treatment with pacritinib in routine clinical settings with platelet count ≥50 x 109/L at the time of treatment initiation with pacritinib. This study will be conducted entirely through medical chart abstraction; all data will be taken from the patient's medical record, with no additional assessments.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult patients must be ≥18 years of age at the index date
  • Patients diagnosed with MF with platelet counts ≥50 x 109/L at the time of treatment initiation with pacritinib. If multiple values are available within 30 days prior to initiating treatment with pacritinib will use the value closest to index date
  • Patients will be required to have ≥1 month of treatment with pacritinib and ≥6 months of observation from the start of pacritinib unless the patient died within 6 months of starting pacritinib
  • If peripheral blasts were evaluated prior to index, they must be <10%. If not evaluated, patients will be included unless a healthcare provider has indicated in the medical record that there is a concern that the patient has transitioned to accelerated/blast phase disease at or prior to index
  • According to local regulations, waivers of consent will be sought for study patients from the appropriate regulatory authorities and/or the independent ethics committee (IEC)/institutional review board (IRB). For patients not covered by waivers of consent, signed and dated informed consent provided by the patient, or the patient's legally authorized representative(s) for patients under the legal age (with patient assent, as applicable), should be obtained before any study-related activities are undertaken.

Exclusion criteria

  • Diagnosis of acute myeloid leukemia prior to index
  • Physician-concern that the patient has transitioned to accelerated/blast phase disease if peripheral blasts were not evaluated
  • Treated with 2 or more JAK inhibitors prior to initiating treatment with pacritinib
  • Treated with pacritinib in a clinical trial setting

Treatment and study plan

Not applicable- observational study

Other

Not Applicable - Observational Study

Primary outcomes

  1. ≥50% spleen length reduction

    Time frame: From the Index Date to Week 24 or best response in spleen reduction, assessed up to 49 months.

  2. ≥20% spleen length reduction

    Time frame: From the Index Date to Week 24 or best response in spleen reduction, assessed up to 49 months.

  3. Change in spleen length

    Time frame: Index to Week 24 and at other timepoints, assessed up to 49 months.

  4. Improvement in spleen size category

    Time frame: Index to Week 24 and at other timepoints, assessed up to 49 months.

  5. Among those with ≥1 MF-related symptom at index Symptom-specific resolution

    Time frame: Index to Week 24 and at other timepoints, assessed up to 49 months.

  6. Among those with ≥1 MF-related symptom at index Decrease in total number of MF-symptoms

    Time frame: Index to Week 24 and at other timepoints, assessed up to 49 months.

  7. Among those with ≥1 MF-related symptom at index Change in total number of MF-symptoms

    Time frame: Index to Week 24 and at other timepoints, assessed up to 49 months.

  8. Change in blood counts (i.e., white blood cells [WBC], platelets, absolute neutrophil counts, peripheral blast percentage)

    Time frame: Index to Week 24 and at other timepoints, assessed up to 49 months.

  9. Among those who are non-transfusion independent (TI) (≥1 RBC transfusion in prior 12 weeks) at index RBC-TI - absence of RBC transfusions over any 12-week period

    Time frame: Index to Week 24 and at other timepoints, assessed up to 49 months.

  10. Among those who are non-transfusion independent (TI) (≥1 RBC transfusion in prior 12 weeks) at index ≥50% reduction in number of RBC units transfused

    Time frame: Index to Week 12 & Index to Week 24

  11. Among those who are non-transfusion independent (TI) (≥1 RBC transfusion in prior 12 weeks) at index ≥50% reduction in monthly rate of RBC units transfused

    Time frame: Index to Week 12 & Index to Week 24

  12. Among those who are non-transfusion independent (TI) (≥1 RBC transfusion in prior 12 weeks) at index change in the number of RBC units transfused

    Time frame: Index to Week 24

  13. Among those who are non-transfusion independent (TI) (≥1 RBC transfusion in prior 12 weeks) at index change in the monthly rate of RBC units transfused

    Time frame: Index to Week 24

  14. Among those with a platelet count <100 x 109/L at index date Absolute increase in platelet counts ≥30 x 109/L without a platelet transfusion in the prior 2 days

    Time frame: Index to best response, assessed up to 49 months.

  15. Among patients with Hb <10 g/dL at index and who are RBC-transfusion dependent (TD) (≥3 RBC units transfused in prior 12 weeks) at index: achieved RBC-TI

    Time frame: 12-Week Period with no RBC transfusions administered during the period

  16. Among patients with Hb <10 g/dL at index and who are not RBC-transfusion dependent (TD) (≥3 RBC units transfused in prior 12 weeks) at index: ≥1.5 g/dL increase in average Hb

    Time frame: 12-Week Period with no RBC transfusions administered during the period

  17. Among patients who have IWG Hb Minor Response at index and are RBC-TD at index ≥50% reduction in RBC transfusion

    Time frame: 12-Week Period without being fully RBC-TI

  18. Among patients who have IWG Hb Minor Response at index and are not RBC-TD at index ≥1 g/dL increase in average Hb

    Time frame: 12-Week Period without being fully RBC-TI

  19. Physician-reported progression to leukemia (AML)

    Time frame: Index to Follow-up, assessed up to 49 months.

  20. Overall survival

    Time frame: Index to Follow-up, assessed up to 49 months.

  21. Leukemia-free Survival

    Time frame: Index to Follow-up, assessed up to 49 months.

  22. Type, dose, and number of MF-directed therapies administered

    Time frame: At Index (Baseline)

  23. Reasons for treatment switch from a prior MF-directed therapy to pacritinib

    Time frame: At Index (Baseline)

  24. Method used to switch from prior JAKi to pacritinib

    Time frame: At Index (Baseline)

  25. Physician reported (or Physician confirmed) JAKi withdrawal syndrome after switching to pacritinib from a different JAKi

    Time frame: Prior to (index date) and after initiation of pacritinib (up to 49 months).

  26. Pacritinib line of therapy, treatment dose and frequency, changes in dose/and or frequency, frequency of dose changes and reasons for change

    Time frame: Prior to (index date) and after initiation of pacritinib (up to 49 months).

  27. Duration of treatment with pacritinib

    Time frame: Prior to (index date) and after initiation of pacritinib (up to 49 months).

  28. Concomitant MF-related medications

    Time frame: Prior to (index date) and after initiation of pacritinib (up to 49 months).

  29. Reason for discontinuation of pacritinib

    Time frame: Prior to (index date) and after initiation of pacritinib (up to 49 months).

  30. Subsequent MF-therapy following discontinuation of pacritinib and time to next Treatment

    Time frame: Prior to (index date) and after initiation of pacritinib (up to 49 months).

  31. Demographic characteristics include age, sex, race/ethnicity, geographic region, and insurance type

    Time frame: At Index (Baseline)

  32. Body mass index (BMI) for all participants enrolled

    Time frame: At Index (Baseline)

  33. Receipt of allo-HSCT among patients referred to allo-HSCT

    Time frame: Index to Week 24

  34. Duration of treatment with pacritinib prior to allo-HSCT

    Time frame: Index to Week 24

  35. Dose of pacritinib prior to allo-HSCT

    Time frame: Index to Week 24

  36. Discontinuation of pacritinib prior to allo-HSCT

    Time frame: Index to Week 24

  37. Treatment with pacritinib during conditioning

    Time frame: Index to Week 24

  38. Dose of pacritinib during condition

    Time frame: Index to Week 24

  39. Duration of treatment with pacritinib after allo-HSCT

    Time frame: Index to Week 24

  40. Dose of pacritinib after allo-HSCT

    Time frame: Index to Week 24

  41. Type of MF for all participants enrolled

    Time frame: At Index (Baseline)

  42. Comorbidities for all participants enrolled

    Time frame: At Index (Baseline)

  43. MF Risk Category for all participants enrolled

    Time frame: At Index (Baseline)

  44. Bone Marrow Fibrosis Grade for all participants enrolled

    Time frame: At Index (Baseline)

  45. Type of MF Mutations for all participants enrolled

    Time frame: At Index (Baseline)

  46. Variant Allele Frequency (VAF) for all participants enrolled

    Time frame: At Index (Baseline)

  47. Number of Driver Mutations for all participants enrolled

    Time frame: At Index (Baseline)

  48. Number of High-Risk Mutations for all participants enrolled

    Time frame: At Index (Baseline)

  49. Karyotype for all participants enrolled

    Time frame: At Index (Baseline)

Study contacts

Contact information is provided by the study sponsor or research team.

Clinical Operations Lead

CONTACT

[email protected]

IQVIA Study Team

CONTACT

[email protected]

617-621-1600

Sponsors and collaborators

Lead sponsor

Swedish Orphan Biovitrum

Industry

Collaborators

  • IQVIA RDS Inc.

Registry information

Official study title

Pacritinib Effectiveness in Real-world Settings (PACER)

Acronym: PACER

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Aug 19, 2026
Registry last updated
Aug 19, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.